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Ploidy status predicts disease-free intervals and short-term
survival in numerous human malignancies (Barlogie et al 1983;
Friedlander et al 1984). In lung cancer, the prognostic value of
ploidy is controversial. The effect of ploidy status on patient
outcome has been investigated particularly in non-small-cell lung
cancers (NSCLC), a group of different histologies including squa-
mous cell carcinoma (SQC), adenocarcinoma (ADC) and large
cell carcinoma (LCC). Although authors from different laborato-
ries have suggested that patients presenting an aneuploid tumour
have a shorter survival than patients presenting a nearly diploid
tumour, others did not find such a difference. Many factors could
explain the differences in estimating the ploidy–survival relation-
ship. Possible interpretation could lie in the heterogeneity of the
abnormal DNA patterns gathered under the common term of
aneuploidy, i.e. hyperdiploidy, hypodiploidy and multiploidy
(Barlogie et al, 1980). Differences in methods used to analyse DNA
content could also have been responsible for the above-mentioned
controversy inasmuch as some studies were founded on flow
cytometry data whereas others used static cytometry. Finally, the
difference might be related to the histological and clinical charac-
teristics of the studied patient population. 
We therefore made a meta-analysis of published studies aimed
at determining the prognostic effect of aneuploidy in surgically
resected NSCLC. 
TRIALS AND METHODS 
Eligibility criteria 
The most conventional definition of ploidy status is as follows:
ploidy was determined for each specimen using DNA index which
represents the ratio of the cell DNA content of tumour G0/1 cells to
the diploid G0/1 peak (2n). A coefficient of variation (CV) for this
DNA index (DI) has been specifically defined for each study. Thus,
a DNA index = 1 defined a near diploid specimen i.e. only one peak
of G0/1 cells in the near diploid region (2n, DNA index = 1) with
few G2M tumour cells in the tetraploid region (4n). Conversely,
tumours presenting a DI of less than [1 – CV] (hypodiploidy) or
over [1 + CV] (hyperdiploid) were classified as aneuploid
NSCLCs, as were tumours sharing multiple aneuploid peaks. 
Aneuploidy and prognosis of non-small-cell lung cancer:
a meta-analysis of published data 
D Choma1, J-P Daurès2, X Quantin1 and JL Pujol1,2
1Thoracic Oncology Unit, Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, 34295 Montpellier Cedex, France; 2Department of
Biostatistics and Epidemiology, University Institute for Clinical Research, Rue de la Cardonille, 34093 Montpellier Cedex 5, France 
Summary In lung cancer, DNA content abnormalities have been described as a heterogeneous spectrum of impaired tumour cell DNA
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lung cancer, the negative effect of aneuploidy has been a subject of controversy inasmuch as studies aimed at determining the survival–DNA
content relationship have reported conflicting results. We made a meta-analysis of published studies aimed at determining the prognostic effect
of aneuploidy in surgically resected non-small-cell lung cancer. 35 trials have been identified in the literature. A comprehensive collection of
data has been constructed taking into account the following parameters: quality of specimen, DNA content assessment method, aneuploidy
definition, histology and stage grouping, quality of surgical resection and demographic characteristics of the analysed population. Among the
4033 assessable patients, 2626 suffered from non-small-cell lung cancer with aneuploid DNA content (overall frequency of aneuploidy: 0.65;
95% CI: (0.64–0.67)). The DerSimonian and Laird method was used to estimate the size effects and the Peto and Yusuf method was used in
order to generate the odds ratios (OR) of reduction in risk of death for patients affected by a nearly diploid (non-aneuploid) non-small-cell lung
cancer. Survivals following surgical resection, from 1 to 5 years, were chosen as the end-points of our meta-analysis. Patients suffering from a
nearly diploid tumour benefited from a significant reduction in risk of death at 1, 2, 3 and 4 years with respective OR: 0.51, 0.51, 0.45 and 0.67
(P < 10–4 for each end-point). 5 years after resection, the reduction of death was of lesser magnitude: OR: 0.87 (P = 0.08). The test for overall
statistical heterogeneity was conventionally significant (P < 0.01) for all 5 end-points, however. None of the recorded characteristics of the
studies could explain this phenomenon precluding a subset analysis. Therefore, the DerSimonian and Laird method was applied inasmuch as
this method allows a correction for heterogeneity. This method demonstrated an increase in survival at 1, 2, 3, 4 and 5 years for patients with
diploid tumours with respective size effects of 0.11, 0.15, 0.20, 0.20 and 0.21 (value taking into account the correction for heterogeneity; 
P < 10–4 for each end-point). Patients who benefit from a surgical resection for non-small-cell lung cancer with aneuploid DNA content prove to
have a higher risk of death. This negative prognostic factor decreases the probability of survival by 11% at one year, a negative effect
deteriorating up to 21% at 5 years following surgery. © 2001 Cancer Research Campaign http://www.bjcancer.com
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To be included in this meta-analysis, studies had to fulfil the
following criteria: estimation of overall survival–DNA content
relationship as aim of the study; inclusion of patients suffering
from histologically proven NSCLC and operated upon in an
attempt at surgical resection; no anticancer treatment (neither
chemotherapy nor radiotherapy) prior to surgical resection; speci-
fication of the nature of both tested specimens and methods of
DNA content assessment; standard ploidy and aneuploidy defini-
tions; clear definition of overall survival as the time from surgery
to the date of death (or date of survival update for censored
patients), comprehensive survival analysis including the
Kaplan–Meier method (Kaplan and Meier, 1958) estimation for
incomplete observations separately analysing patient groups
according to the DNA content. Alternative survival analysis using
actuarial survival curves were also considered as eligible for this
analysis. Finally, a 2-year minimal median follow-up was
required. Studies mainly devoted to the analysis of NSCLC
patients which also included a small proportion of SCLC were
considered as eligible depending on separate survival analyses. 
Studies with one or more of the following methodological
issues were not included in the meta-analysis: histology not
reported; analysis of DNA content aimed at assessing cell kinetic
parameters such as identification of the percent of cells in S phase
rather than ploidy status; unconventional survival report (lack of
estimation of survival according to time, small subgroup analysis);
unknown relationship between death and lung cancer; follow-up
shorter than 2 years. In addition, studies mainly aimed at analysing
survival according to treatment modalities (post-operative treat-
ment, diagnostic only surgery) were not considered as eligible. 
Selection of trials 
A computerized bibliography was extracted from MEDLINE and
CANCERLIT (CancerNet™) databases using medical subject
headings for the following terms: lung neoplasm, lung carcinoma,
non-small-cell, ploidy or DNA content, prognosis. The search for
publications in any language, was carried out from 1966 to the end
of 1999 inclusive. Afterwards, the manual selection of relevant
studies was based upon summary analysis. The reprint of each
study was carefully analysed regarding the different eligibility
criteria. In addition to the above-mentioned procedure, bibliogra-
phies of selected full papers were screened in order to disclose
other relevant articles.
Collection of data 
A comprehensive collection of data has been constructed taking
into account the following parameters: year of publication, aim of
the study, type of sampled specimens (paraffin embedded spec-
imen versus fresh tissue specimens), DNA content assessment
method (flow cytometry versus static cytometry), aneuploidy defi-
nition, histology sub-groups and stage grouping, quality of
surgical resection and demographic characteristics of the analysed
population. 
Survivals after surgical resection, from 1 to 5 years, were
chosen as the end-points of our meta-analysis. These outcomes
were assessed as follows: the parameters were directly graphically
measured from magnification of publication graphs. When the
data were directly reported in the text, comparisons with graphic
assessment were in good agreement. An attempt to contact the
first author of each selected article was made in order to obtain
permission to use the data and to know whether there had been any
update of the study following its publication. 
Statistics 
2 methods were used in order to estimate the effects of ploidy upon
survival in surgically resected NSCLC patients. The Yusuf and
Peto method produces odds ratio (OR) and a 95% confidence
interval together with the value of the heterogeneity test (Yusuf
et al, 1985). In addition, the DerSimonian and Laird method was
used in order to estimate the size effects upon the different para-
meters and their 95% confidence intervals were calculated
(DerSimonian and Laird, 1986). For this method the value and the
95% confidence interval were corrected taking into account the
heterogeneity where this latter parameter was statistically signifi-
cant. 
RESULTS 
A total of 35 studies fulfilled the criteria of selection (Zimmerman
et al, 1987; Tirindelli-Danesi et al, 1987; Ten Velde et al, 1988;
Volm et al, 1988; Yamaoka et al, 1989; Cibas et al, 1989; Dazzi 
et al, 1990; Isobe et al, 1990; Sahin et al, 1990; Shiota et al, 1990;
Miyamato et al, 1991; Mizumoto et al, 1991; Liewald et al, 1992;
Ogawa et al, 1992; Filderman et al, 1992; Morkve et al, 1993; Cheon
et al, 1993; Pence et al, 1993; Rice et al, 1993; Ichinose et al, 1993;
Lima et al, 1993; Shimizu et al, 1993; Yu et al, 1993; Usuda et al,
1994; Salvati et al, 1994; Tanaka et al, 1995; Pujol et al, 1996;
Huang et al, 1996; Nagai et al, 1996; Jeanfaivre et al, 1997;
Muguerza et al, 1997; Kolodzeijski et al, 1997; Graziano et al,
1997; Dalquen et al, 1997; Asamura et al, 1999; (Table 1)). Among
the 4033 assessable patients, 2626 suffered from NSCLC with
aneuploid DNA content (overall frequency of aneuploidy: 0.65;
95% Cl: (0.64–0.67)). All studies used flow cytometry measure-
ment of DNA content except 2 which were based on static cytom-
etry. 15 studies were prospectively conducted whereas 16
retrospectively investigated specimens from tumour banks. For the
4 remaining studies the nature of the studies population was
unknown. NSCLC was the targeted population for all studies.
However, three studies including less than 10% SCLC among a
large NSCLC population where also taken into account (Ogawa
et al, 1992; Usuda et al, 1994; Pujol et al, 1996). These SCLC
cases represented 0.4% of the whole population. 
Some studies reporting ploidy in NSCLC were considered as
being outside the scope of this meta-analysis. 4 studies could not
be selected owing to the lack of overall survival data although they
appropriately reported disease-free (or relapse-free) survival
(Volm et al, 1988; Carp et al, 1992; Costa et al, 1996; Roberts et al,
1998). 3 studies aimed at determining the prognostic effect of
DNA content characteristics other than the classical dichotomy
diploidy–aneuploidy. These characteristics targeted as prognostic
factors were: type of aneuploidy patterns (Bunn et al, 1983),
percent of cells in the aneuploid G1 peak (Van Bodegom et al,
1989) and hypodiploid/hypertetraploidy patterns (Stipa et al,
1993). One study (Del Carlo Bernardi et al, 1997) defined diploid
tumours as tumours presenting a DI ≤ 1.2 a feature shared by
hypodiploid tumours (Barlogie et al, 1980; Stipa et al, 1993). 3
publications were preliminary reports of DNA content–survival
relationship (Salvati et al, 1989; Ichinose et al, 1991; Ogawa et al,
1991) but otherwise subsequently reported by the respective
groups (Ogawa et al, 1992; Ichinose et al, 1993; Salvati et al,16 D Choma et al 
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.
 1994). 7 publications aimed at determining the relationship
between ploidy status and other clinical and biological features
such as c-erbB-2 and L-myc expressions (Chiba et al, 1993), Ki-67
growth-fraction evaluation (Simony et al, 1990), stage grouping
(Ikeda et al, 1995), S-phase (Granone et al, 1993; Visakorpi et al,
1995), p53 gene mutations (Casson et al, 1994), or bromod-
eoxyuridine labelling (Shimosato et al, 1989). In these studies the
survival data were neither exhaustively reported nor considered as
the primary end-point of the experiment. Finally one study
aimed at describing a new static cytometric method and secon-
darily reported descriptive relapse data (Blondal and Bengtson,
1981). 
Peto and Yusuf 
Patients suffering from nearly diploid tumours benefited from a
significant reduction in risk of death at 1, 2, 3 and 4 years with
respective OR: 0.51, 0.51, 0.45 and 0.67 (P < 10–4 for each end-
point; Figures 1–4). 5 years after resection, the reduction of death
was of lesser magnitude: OR: 0.87 (P = 0.08; Figures 5). The test
for overall statistical heterogeneity was conventionally significant
(P < 0.01; Table 2) for all 5 end-points, however. None of the
recorded characteristics of the studies were able to explain this
phenomenon precluding a subset analysis. 
DerSimonian and Laird 
The DerSimonian and Laird method was applied inasmuch as this
method allows a correction for heterogeneity. This method demon-
strated an increase in survival at 1, 2, 3, 4 and 5 years for patients
with diploid tumours with respective size effects of 0.11, 0.15,
0.20, 0.20 and 0.21 (value taking into account the correction for
heterogeneity; P < 10–4 for each end-point). 
DISCUSSION 
DNA content analysis has been proposed to assess cell kinetics
insofar as the DNA histogram allows the identification of the
percent of cells in S phase. However, the assessment of S phase is
frequently hampered by the overlap between aneuploid tumour-
cell population and diploid non-malignant cell population. Thus, in
human malignancies, DNA content analysis is mainly used to
evaluate the occurrence of aneuploid cell population, an abnor-
mality known to characterize malignant cells (Barlogie et al,
1980). The study of cell kinetics has been proposed as a reliable
prognostic parameter in human malignancies (Barlogie et al, 1980;
Latreille et al, 1980; Friedlander et al, 1984). Aneuploidy can
predict short-term survival in many solid tumours (Wolley et al,
1982; Auer et al, 1984; Friedlander et al, 1984; Bondeson et al, 1986;
Matsura et al, 1986). In lung cancer the prognostic significance of an
abnormal DNA content might be regarded, in a logical way, as
consistent with knowledge of tumour biology for this disease.
However, published studies have generated conflicting results and
currently the negative effect of aneuploidy in NSCLC is still
controversial. 
In this study we used a meta-analytic approach to this question
in an attempt to determine the ploidy-survival relationship and,
depending on its existence, the magnitude of the effect. One may
hypothesize that, due to the nature of the herein meta-analysis
based on published data, a possible bias was introduced as our
procedure did not allow the disclosure of unpublished studies. A
direct comparison of meta-analysis on medical literature and meta-
analysis on individual patient data has been made in the setting of
chemotherapy in ovarian cancer (Stewart and Parmar, 1993). This
study suggested possible differences in estimated treatment effect
due to patient exclusions and shorter length of follow-up in the
former technique. However, the meta-analysis reported here takes
into account 35 studies which as a whole included over 4000
patients suffering from NSCLC. A long-term survival end-point
has been chosen to avoid overestimation of effect by a short
follow-up period. No apparent effect of epoch appeared when year
of publication was taken into account. The proportion of tumours
presenting an aneuploid DNA content is set at 64% and was
reported homogeneously throughout the panel of studies analysed.
One can therefore speculate that publication bias could be minimal
although remaining unknown. 
The different study designs are similar. However, statistical
heterogeneity has been detected by both meta-analysis methods
regarding survival estimation. Using the DerSimonian and Laird
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Figure 1 Odds ratio and 95% confidence interval of mortality at 1 year for
patients operated upon for a NSCLC with nearly diploid DNA content 
(P < 10–4). Results are expressed as individual and overall Ors; vertical bar,
and their respective 95% confidence intervals; horizontal bar. ORs lower than
1 indicate a reduction in risk of death for patients affected by a diploid
NSCLC. See in Table 2, test for heterogeneity method this heterogeneity has been taken into account. In addition,
the magnitude of the survival effect has been set by the latter
method as a complementary estimation of prognosis aside from
the classical OR determination using the Peto and Yusuf method.
There is, so far, no definitive explanation for the heterogeneity.
Among the different hypotheses, we investigated whether the
method of analysis could be responsible for the difference. Flow
cytometry is considered as the standard method to analyse DNA
content histograms after propidium iodine staining of a single-cell
suspension. This method takes into account thousands of cells.
Static cytometry has been proposed as an alternative method. It
analyses cytological prints of the tumour after Feulgen staining.
This second method only analyses a few hundred cells. Although
this number is lower than the one analysed by flow cytometry, the
computer-assisted image processor is able to distinguish between
tumour cells to be analysed and tumour-infiltrating lymphocytes.
In addition, studies carried out in order to compare the 2 methods
demonstrated the reliability of ploidy analysis using static cytom-
etry (Friedlander et al, 1984; Oud et al, 1989). Thus, static
computer-assisted cytometry is considered as a reliable means of
analysing ploidy in situ. In this meta-analysis, both studies based
on this technique produced results in accordance with the final
survival–aneuploidy relationship as generated by the meta-
analysis. Neither the nature of the samples, nor the histology or
stage of the studied population could be a putative reason for the
heterogeneity. In particular, published studies seldom reported on
difference in aneuploidy based on histological subgroup (i.e.
adenocarcinoma, SQC or LCC). Consequently, it is not possible to
determine whether or not difference in NSCLC histology from one
study to the other could explain the statistical heterogeneity. In
addition, the distribution of aneuploid and diploid tumours by
stage has been recorded in our database whenever the data was
reported by each study. Out of the 18 studies with detail analysis
by stages, the respective percentage of aneuploid tumours in stage
I, stage II and stage III was 58, 57 and 70%. Therefore, it seems
unlikely that the statistical heterogeneity regarding survival esti-
mation of the whole meta-analysis, belongs to the distribution of
stage grouping of the different accrued populations, insofar as the
frequency of aneuploidy did not differ from one stage group to the
other. 
The type of sample analysed could hardly be considered as a
possible inductor of heterogeneity across the panel of studies
18 D Choma et al 
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Figure 2 Odds ratio and 95% confidence interval of mortality at 2 years for
patients operated upon for a NSCLC with nearly diploid DNA content
(symbols as in Figure 1; P = < 10–4) 
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Figure 3 Odds ratio and 95% confidence interval of mortality at 3 years for
patients operated upon for a NSCLC with nearly diploid DNA content
(symbols as in Figure 1; P = < 10–4) Meta-analysis of ploidy in NSCLC 19
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Figure 4 Odds ratio and 95% confidence interval of mortality at 4 years for
patients operated upon for a NSCLC with nearly diploid DNA content
(symbols as in Figure 1; P = < 10–4) 
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Figure 5 Odds ratio and 95% confidence interval of mortality at 5 years
for patients operated upon for a NSCLC with nearly diploid DNA content
(P < 10–4) (symbols as in Figure 1; P = 0.08). 
Table 2 Results of Peto and Yusuf meta-analysis 
Endpoint OR Lower Upper P –logOR/ Heterogeneity Degree  of  P heterogeneity 
s s(logOR) freedom
1 y 0.5130 0.4323 0.6087 < 0.0001 6.74 Q = 76.60 32 P < 0.01 
2 y 0.5092 0.4387 0.5837 < 0.0001 9.24 Q = 59.00 33 P < 0.01 
3 y 0.4461 0.3872 0.5139 < 0.0001 11.17 Q = 87.50 33 P < 0.01 
4 y 0.6666 0.5731 0.7753 < 0.0001 5.26 Q = 119.2 29 P < 0.01 
5 y 0.8742 0.7510 1.0170 0.08 1.74 Q = 123.9 28 P < 0.01 
Odds ratios indicate the reduction of risk of death for patients presenting a nearly diploid tumour. 
Table 3 Results of Dersimonian and Laird meta-analysis 
Endpoint Diploidy Aneuploidy Y* Y : 95% confidence  P Heterogeneity Degrees of  P
interval freedom heterogeneity 
1 y P = 0.871 P = 0.763 0.11 0.07; 0.15 < 0.0001 Q = 111.3 32 < 0.005 
2 y P = 0.739 P = 0.590 0.15 0.10; 0.20 < 0.0001 Q = 78.42 33 < 0.005 
3 y P = 0.660 P = 0.460 0.20 0.14; 0.26 < 0.0001 Q = 117.62 33 < 0.005 
4 y P = 0.603 P = 0.400 0.20 0.13; 0.27 < 0.0001 Q = 142.58 29 < 0.005 
5 y P = 0.604 P = 0.391 0.21 0.15; 0.28 < 0.0001 Q = 105.53 28 < 0.005 
*Size effect according to DerSimonian and Laird’s method. Corrected values taking into account a significant heterogeneity. owing to the fact that there is a good agreement between the DNA
histograms obtained from fresh tissue and paraffin-embedded
specimens where flow cytometry has been done in parallel
(Hedley et al, 1983). A possible hidden explanation of the statis-
tical heterogeneity lies in the well-established diversity of DNA
content histograms and growth fraction estimations in a given
specimen (Sara et al, 1986; Oud et al, 1989; Simony et al, 1990;
Stipa et al, 1993). Besides this heterogeneity, one can emphasize
that aneuploidy is a common terminology designating different
histogram patterns. Multiploidy and hypodiploidy might be
underestimated in some specimens. In multiple myeloma and
breast cancer attention has been paid to the occurrence of these 2
particular ploidy status (Coulson et al, 1984; Smith et al, 1986). A
similar observation has been made in lung cancer in which
hypodiploidy seems to indicate a particularly poor outcome
(Pujol et al, 1996). 
Hitherto, the prognosis of patients with surgically resected
NSCLC is mainly determined using two main prognostic variables,
i.e. the stage of the disease and the performance status. During the
past decade, the search for genetic markers of NSCLC has
emerged in an attempt to predict poor outcome of this disease and
to help the clinician in deciding whether there is a case for adju-
vant chemotherapy. Abnormal nuclear content has long been
known as a conclusive marker of malignancy and was found in
increased frequency in solid tumours. It is noteworthy that the
65% overall frequency of aneuploidy, as observed in this meta-
analysis is consistent with the 67% frequency reported in 4941
patients suffering from various human malignancies (Barlogie et
al, 1983). During the 1990s, after an initial period of enthusiasm
for aneuploidy as a putative prognostic marker in NSCLC, the
interest seemed to decrease. This might be explained partially by
the fact that conflicting results arose from different studies.
However, the meta-analysis described above seems to provide
additional clues in favour of a prognostic effect of aneuploidy in
this disease. DNA content analysis provides a unique insight into
the cellular heterogeneity and the genotypic instability of NSCLC.
Chromosomal instability leads to abnormal regulation of gene
expression and aneuploidy. This latter characteristic might be a
critical factor for phenotypic diversification towards a metastatic
phenotype (Nicolson, 1987). 
Notwithstanding the heterogeneity across the studies, the herein
meta-analysis allows the conclusion that patients who benefit from
a surgical resection for NSCLC with aneuploid DNA content
prove to have a higher risk of death. The survival probability for
patients having an aneuploid tumour is decreased by 11% at one
year, a negative effect deteriorating up to 21% at 5 years following
surgery. 
ACKNOWLEDGEMENTS 
The authors wish to thank Mrs Jo Baïssus for help in preparing the
manuscript. Supported by a grant from the French League Against
Cancer (Hérault committee). 
REFERENCES 
Asamura H, Ando M, Matsuno Y and Shimosato Y (1999) Histopathologic
prognostic factors in resected adenocarcinomas. Chest 115: 1018–1024 
Auer G, Eriksson E, Azavedo E, Caspersson T and Wallgren A (1984) Prognostic
significance of nuclear DNA content in mammary adenocarcinomas in humans.
Cancer Res 44: 394–396 
Barlogie B, Drewinko B, Schumann J, Gohde W, Dosik G, Latreille J, Johnston DA
and Freireich EJ (1980) Cellular DNA content as a marker of neoplasia in man.
Am J Med 69: 195–203 
Barlogie B, Raber MN, Shumann J, Johnson TS, Drewinki B, Swartzendruber DE,
Göhde W, Andreeff M and Feireich EJ (1983) Flow cytometry in clinical
cancer research. Cancer Res 43: 3982–3997 
Blondal T and Bengtsson A (1981) Nuclear DNA measurements in squamous cell
carcinoma of the lung: a guide for prognostic evaluation. Anticancer Res 1:
79–86 
Bondeson L, Azavedo E, Bondeson AG, Caspersson T and Ljungberg O (1986)
Nuclear DNA content and behavior of oxyphil thyroid tumors. Cancer 58:
672–675 
Bunn PA, Carney DN, Gazdar AF, Whang-Peng J and Matthews MJ (1983)
Diagnostic and biological implications of flow cytometry DNA content
analysis in lung cancer. Cancer Res 43: 5026–5032 
Carp NZ, Ellison DD, Brophy PF, Watts P, Chang MC and Keller SM (1992) DNA
content in correlation with post-surgical stage in non-small-cell lung cancer.
Ann Thorac Surg 53: 680–683 
Casson AG, McCuaig S, Craig I, Ayed A, Inculet R, Kerkvliet N and O’Malley F
(1994) Prognostic value and clinicopathologic correlation of p53 gene
mutations and nuclear DNA content in human lung cancer: a prospective study.
J Surg Oncol 56: 13–20 
Cheon SH, Sohn HY, Chang J, Kim SK, Ko EH, Kim SK, Lee WY, Lee DY, 
Shin DH, Jeong ET and Chung HT (1993) Flow cytometric analysis of DNA
ploidy in primary non-small-cell carcinoma of the lung in Korea. Yonsei Med J
34: 365–370 
Chiba W, Sawai S, Hanawa T, Ishida H, Matsui T, Kosaba S, Watanabe S,
Hatakenaka R, Matsubara Y, Funatsu T, Ikeda S, Kinoshita M and Matsumoto
H (1993) Correlation between DNA content and amplification of oncogenes 
(c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of
resected lung cancer. Jpn J Cancer Chemother 20: 824–827 
Cibas ES, Melamed MR, Zaman, MB and Kimmel M (1989) The effect of tumor
size and tumor cell DNA content on the survival of patients with stage I
adenocarcinoma of the lung. Cancer 63: 1552–1556 
Costa A, Silverstrini R, Mochen C, Lequaglie C, Boracchi P, Faranda A, Vessecchia G
and Ravasi G (1996) p53 expression, DNA ploidy and S-pase cell fraction in
operable locally advanced non-small-cell lung cancer. Br J Cancer 73: 914–919 
Coulson BP, Thornthwaite JT, Weelley TW, Sugarbaker EV and Seckinger D (1984)
Prognostic indicators including DNA histogram type, receptor content, and
staging related to human breast cancer patient survival. Cancer Res 44:
4187–4196 
Dalquen P, Moch H, Feichter G, Lehmann M, Solèr M, Stulz P, Jordan P, Torhorst J,
Mihatsch MJ and Sauter G (1997) DNA aneuploidy, S-phase fraction, nuclear
p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Arch
431: 173–179 
Dazzi H, Thatcher N, Hasleton PS and Swindell R (1990) DNA analysis by flow
cytometry in non-small-cell lung cancer: relationship to epidermal growth
factor receptor, histology, tumour stage and survival. Respir Med 84: 217–223 
Del Carlo Bernardi F, Antonangelo L, Beyruti R, Takagaki T, Nascimento Saldiva PH
and Capelozzi VL (1997) A prognostic model of survival in surgically resected
squamous cell carcinoma of the lung using clinical, pathologic and biologic
markers. Mod Pathol 10: 992–1000 
DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. Control Clin
Trials 7: 177–188 
Filderman AE, Silvestri GA, Gatsonis C, Luthringer DJ, Honig J and Flynn SD
(1992) Prognostic significance of tumor proliferative fraction and DNA
content in stage I non-small-cell lung cancer. Am Rev Respir Dis 146:
707–710 
Friedlander ML, Hedley DW and Taylor IW (1984a) Clinical and biological
significance of aneuploidy in human tumours. J clin Pathol 37: 961–974 
Friedlander ML, Hedley DW, Taylor IW, Russell P, Coastes AS and Tattersall MHN
(1984b) Influence of cellular DNA content on survival in advanced ovarian
cancer. Cancer Res 44: 397–400 
Granone P, Cardillo G, Rumi E, D’Ugo D, Rumi C, Ciletti S, Margaritora S,
Terribile D and Picciocchi A (1993) DNA flow cytometric analysis in patients
with operable non-small-cell lung carcinoma. Eur J Cardio-thorac Surg 7:
351–355 
Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB and Kohman LJ (1997)
Blood group antigen A and flow cytometric analysis in resected early-stage
non-small-cell lung cancer. Clin Cancer Res 3: 87–93 
Hedley DW, Friedlander ML, Taylor IW, Rugg CA and Musgrove EA (1983)
Method for analysis of cellular DNA content of paraffin-embedded
pathological material using flow cytometry. J Histochem Cytochem 31:
1333–1335 
20 D Choma et al 
British Journal of Cancer (2001) 85(1), 14–22 © 2001 Cancer Research CampaignHuang MS, Colby TV, Therneau TM, Daly RC and Gonchoroff NJ (1996) DNA
ploidy and protein content in bronchioloalveolar carcinoma multi-variable flow
cytometry. Cytometry 26: 253–259 
Ichinose Y, Hara N, Ohta M, Motohiro A, Kuda T and Aso H (1991) Postoperative
adjuvant chemotherapy in non-small-cell lung cancer: prognostic value of DNA
ploidy and post-recurrent survival. J Surg Oncol 46: 15–20 
Ichinose Y, Hara N, Ohta M, Yano T, Maeda K, Asoh H and Katsuda Y (1993) Is T
factor of the TNM staging system a predominant prognostic factor in
pathologic stage I non-small-cell lung cancer? J Thorac Cardiovasc Surg 106:
90–94 
Ikeda N, McAulay C, Lam S, Garner DM, Payne PW, Kato H, Konaka C and Palcic B
(1995) Use of high-resolution cytometry in predicting the biologic behavior of
T1 adenocarcinoma of the lung. Analyt Quant Cytol Histol 17: 69–74 
Isobe H, Miyamoto H, Shimizu T, Haneda H, Hashimoto M, Inoue K, Mizuno S and
Kawakami Y (1990) Prognostic and therapeutic significance of the flow
cytometric nuclear DNA content in non-small-cell lung cancer. Cancer 65:
1391–1395 
Jeanfaivre T, Chassevent A, Geslin J, Larra F and Tuchais E (1997) Valeur
pronostique de la cytometrie en flux dans les cancers bronchiques
epidermoides. Etude Retrospective a propos de 61 cas. Bull Cancer 84:
597–602 
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete
observations. J Am Stat Assoc 53: 457–481 
Kolodziejski L, Niezabitowski A and Gasinska A (1997) Clinical and flow
cytometric prognostic factors in surgically treated squamous cell lung cancer.
Lung Cancer 16: 173–182 
Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B and Alexanian R (1980)
Cellular DNA content as a marker of human multiple myeloma. Blood 55:
403–408 
Liewald F, Hatz R, Storck M, Orend KH, Weiss M, Wulf G, Valet G and Sunder-
Plassmann L (1992) prognostic value of deoxyribonucleic acid aneuploidy in
primary non-small-cell lung carcinomas and their metastases. J Thorac
Cardiovasc Surg 104: 1476–1482 
Lima C, Matsui K, Kitagawa M, Mizushima Y, Noto H and Miwa A (1993) Analysis
of prognostic factors in patients with resected peripheral T1 adenocarcinoma of
the lung. Path Res Pract 189: 1149–1153 
Matsura H, Sugimachi K, Ueo H, Kuwano H, Koga Y and Okamura T (1986)
Malignant potentiality of squamous cell carcinoma of the esophagus
predictable by DNA content. Cancer 57: 1810–1814 
Miyamoto H, Harada M, Isobe H, Akita HD, Haneda H, Yamaguchi E, Kuzumaki N
and Kawakami Y (1991) Prognostic value of nuclear DNA content and
expression of the ras oncogene product in lung cancer. Cancer Res 51:
6346–6350 
Mizumoto T, Tokui T, Kusagawa H, Sato T, Wada K, Den T, Kimura M, Namikawa S
and Kusagawa M (1991) DNA analysis of resected pulmonary
adenocarcinoma. Nippon Kyobu Geka Gakkai Zasshi 39: 1870–1875 
Morkve O, Halvorsen OJ, Skjaerven R, Stangeland L, Gulsvik A and Laerum OD
(1993) Prognostic significance of p53 protein expression and DNA ploidy in
surgically treated non-small-cell lung carcinomas. Anticancer Res 13: 571–578 
Muguerza JM, Diez M, Torres AJ, Lopez-Asenjo JA, Picardo AL, Gomez A,
Hernando F, Cayon R, Granell J and Balibrea JL (1997) Prognostic value of
flow cytometric DNA analysis in non-small-cell lung cancer: rationale of
sequential processing of frozen and paraffin-embedded tissue. World J Surg 21:
323–329 
Nagai S, Chiba W, Ikeda S, Matsumoto H, Fujimoto T, Ishida H, Wazawa H,
Hanawa T, Yamashita N, Yasuda Y, Matsubara Y, Hatakenaka R and Funatsu T
(1996) Flow cytometric analysis of the DNA content of resected non-small-cell
lung cancer with reference to long–term follow-up. Jpn J Cancer Chemother
23: 130–134 
Nicolson, G.L (1987) Tumor cell instability, diversification, and progression to the
metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47:
1473–1487 
Ogawa JI, Iwazaki M, Tsurumi T, Inoue H and Shohtsu A (1991) Prognostic
implications of DNA histogram, DNA content, and histologic changes of
regional lymph nodes in patients with lung cancer. Cancer 67: 1370–1376 
Ogawa JI, Tsurumi T, Inoue H and Shohtsu A (1992) Relationship between tumor
DNA ploidy and regional lymph node changes in lung cancer. Cancer 69:
1688–1695 
Oud PS, Pahlplatz MMM, Beck JLM, Wiersma–Van Tilburg A, Wagenaar SJ and
Vooijs GP (1989) Image and flow cytometry of small cell carcinoma of the
lung. Cancer 64: 1304–1309 
Pence JC, Kerns BJM, Dodge RK and Iglehart JD (1993) Prognostic significance of
the proliferation index in surgically resected non-small-cell lung cancer. Arch
Surg 128: 1382–1390 
Pujol JL, Simony J, Jolimoy G, Jaffuel D, Demoly P, Quantin X, Marty-Ane C,
Boher JM, Charpentier R and Michel FB (1996) Hypodiploidy, Ki-67 growth
fraction and prognosis of surgically resected lung cancers. Br J Cancer 74:
964–970 
Rice TW, Bauer TW, Gephardt GN, Medendorp SV, McLain DA and Kirby TJ
(1993) Prognostic significance of flow cytometry in non-small-cell lung cancer.
J Thorac Cardiovasc Surg 106: 210–217 
Roberts HL, Komaki R, Allen P and EI-Naggar AK (1998) Prognostic significance
of DNA content in stage I adenocarcinoma of the lung. Int J Radiation
Oncology Biol Phys 41: 573–578 
Sahin AA, Ro JY, EI-Naggar AK, Lee JS, Ayala AG, Teague K and Hong WK
(1990) Flow cytometric analysis of the DNA content of non-small-cell lung
cancer. Cancer 65: 530–537 
Salvati F, Teodori L, Gagliardi L, Signora M, Aquilini M and Storniello G (1989)
DNA flow cytometric studies of 66 human lung tumors analyzed before
treatment. Prognostic implications. Chest 96: 1092–1098 
Salvati F, Teodori L, Trinca ML, Pasquali-Lasagni R and Gohde W (1994) The
relevance of flow-cytometric DNA content in the evaluation of lung cancer. 
J Cancer Res Clin Oncol, 120: 233–239 
Sara A and EI-Naggar AK (1991) Intratumoral DNA content variability: a study of
non-small-cell lung cancer. Am J Clin Pathol 96: 311–317 
Shimizu J, Watanabe Y, Oda M, Hayashi Y, Ota Y, Morita K and Arano Y (1993)
Results of surgical treatment of stage I lung cancer. Nippon Geka gakkai Zasshi
94: 505–510 
Shimosato Y, Asamura H, Yoshida K, Noguchi M, Nakajima T and Mukai K (1989)
Factors possibly affecting the degree of malignancy in adenocarcinoma of the
lung. DNA content and Bromodeoxyuridine (Brdu) labeling index. Chest S96:
37–38 
Shiota T, Konishi T, Kosaba S, Mitsuoka A, Matsubara Y, Hatakenaka R, Funatsu T,
Ikeda S, Matsumoto H and Ishigami F (1990) Flow cytometric analysis of
cellular DNA content of lung cancer with reference to survival. Nippon Kyobu
Geka Gakkai Zasshi 38: 2364–2369 
Simony J, Pujol JL, Radal M, Ursule E, Michel FB and Pujol H (1990) In situ
evaluation of growth fraction determined by monoclonal antibody Ki-67 and
ploidy in surgically resected non-small-cell lung cancers. Cancer Res 50:
4382–4387 
Smith L, Barlogie B and Alexanian R (1986) Biclonal and hypodiploid multiple
myeloma. Am J Med 80: 841–843 
Stewart LA and Parmar MK (1993) Meta-analysis of the literature or of individual
patient data: is there a difference? Lancet 341: 418–422 
Stipa S, Tirenidelli-Danesi D, Modini C, Cicconetti F, Mauro F, Schillici A, Mecozzi
A, Nicolanti V, Stipa F, Mancini M, Bangrazi C, and Botti C (1993) The
importance of heterogeneity and of multiple site sampling in the prospective
determination of deoxyribonucleic acid flow cytometry. Surg Gynecol Obstet
176: 427–434 
Tanaka I, Masuda R, Furuhata Y, Inoue M, Fujiwara M and Takemura T (1995) Flow
cytometric analysis of the DNA content of adenocarcinoma of the lung,
especially for patients with stage I disease with long term follow-up. Cancer
75: 2461–2465 
Ten Velde GPM, Schutte B, Vermeulen A, Volovics A, Reynders MMJ and Blijham
GH (1988) Flow cytometric analysis of DNA ploidy level in paraffin-embedded
tissue of non-small-cell lung cancer. Eur J Cancer Clin Oncol 24: 455–460 
Tirindelli-Danesi D, Teodori L, Mauro F, Modini C, Botti C, Cicconetti F and Stipa S
(1987) Prognostic significance of flow cytometry in lung cancer. A 5-year
study. Cancer 60: 844–851 
Usuda K, Saito Y, Aikawa H, Sakurada A, Chen Y, Takahashi S, Kanma K, Sato M,
Sagawa M and Fujimura S (1994) Flow cytometric analysis of nuclear DNA
content of lung cancer. Correlation between nuclear DNA content and tumor
doubling time. J Jpn Assn Thorac Surg 42: 486–491 
Van Bodegom PC, Baak JPA, Stroet-Van Galen C, Schipper NW, Wisse-Brekelmans
ECM, Vanderschueren RGJRA and Wagenaar SS (1989) The percentage of
aneuploidy cells is significantly correlated with survival in accurately staged
patients with stage 1 resected squamous cell lung cancer and long term follow-
up. Cancer 63: 143–147 
Visakorpi T, Holli K and Hakama M (1995) High cell proliferation activity
determined by DNA flow cytometry and prognosis in epidermoid lung
carcinoma. Acta Oncol 34: 605–609 
Volm M, Bak M, Hanh EW, Mattern J and Weber E (1988a) DNA and S-phase
distribution and incidence of metastasis in human primary lung carcinoma.
Cytometry 9: 183–188 
Volm M, Hahn EW, Mattern J, Muller T, Vogt-Moykopf I and Weber E (1988b) Five-
year follow-up study of independent clinical and flow cytometric prognostic
factors for the survival of patients with non-small-cell lung carcinoma. 
Cancer Res 48: 2923–2928 
Meta-analysis of ploidy in NSCLC 21
British Journal of Cancer (2001) 85(1), 14–22 © 2001 Cancer Research Campaign22 D Choma et al 
British Journal of Cancer (2001) 85(1), 14–22 © 2001 Cancer Research Campaign
Wolley RC, Schreiber K, Koss LG, Karas M and Sherman A (1982) DNA
distribution in human colon carcinomas and its relationship to clinical behavior.
J Nat Cancer Inst 69: 15–22 
Yamaoka N, Uchiyama Y, Kimino K, Akamine S, Matsuo S and Tsuji K (1989) The
prognostic significance of nuclear DNA content in non-small-cell lung
carcinoma. Nippon Geka Gakkai Zasshi 91: 1608–1616 
Yu J, Shaeffer J, Zhu A, Kuban DA, EI-Mahdi AM and Philput CB (1993) 
Flow cytometric DNA content and clinical outcome in patients with 
non-small-cell lung cancer given postoperative radiation therapy. Cytometry
14: 428–432 
Yusuf S, Cellins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ and Hennekens
CH (1985) Intravenous and intracoronary fibrinolytic therapy in acute
myocardial infarction: overview of results in mortality, reinfarction and side
effects for 33 randomised clinical trials. Eur Heart J 6: 556–585 
Zimmerman PV, Bint MH, Hawson GAT and Parsons PG (1987) Ploidy as a
prognostic determinant in surgically treated lung cancer. Lancet 2: 530–533 